

Abacavir with dolutegravir and lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 451, lamivudine p. 455, dolutegravir p. 446.

● INDICATIONS AND DOSE

HIV infection

► BY MOUTH

- Child 12–17 years (body-weight 40 kg and above): 1 tablet once daily

- **INTERACTIONS** → Appendix 1: abacavir · dolutegravir · lamivudine
- **RENAL IMPAIRMENT** Avoid *Triumeq*[®] if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².
- **PATIENT AND CARER ADVICE**
Missed doses If a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

- *Triumeq* (ViiV Healthcare UK Ltd)
Dolutegravir (as Dolutegravir sodium) 50 mg, Lamivudine 300 mg, Abacavir (as Abacavir sulfate) 600 mg *Triumeq* 50mg/600mg/300mg tablets | 30 tablet [PoM](#) £798.16

Abacavir with lamivudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 451, lamivudine p. 455.

● INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals

► BY MOUTH

- Child 12–17 years (body-weight 40 kg and above): 1 tablet once daily

- **INTERACTIONS** → Appendix 1: abacavir · lamivudine
- **RENAL IMPAIRMENT** Avoid *Kivexa*[®] if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².
- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

- **Abacavir with lamivudine (Non-proprietary)**
Lamivudine 300 mg, Abacavir 600 mg *Abacavir* 600mg / Lamivudine 300mg tablets | 30 tablet [PoM](#) £352.25 DT = £190.00 | 30 tablet [PoM](#) £224.56 DT = £190.00 (Hospital only)
- *Kivexa* (ViiV Healthcare UK Ltd)
Lamivudine 300 mg, Abacavir 600 mg *Kivexa* 600mg/300mg tablets | 30 tablet [PoM](#) £352.25 DT = £190.00

Abacavir with lamivudine and zidovudine

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 451, lamivudine p. 455, zidovudine p. 457.

● INDICATIONS AND DOSE

HIV infection (use only if patient is stabilised for 6–8 weeks on the individual components in the same proportions)

► BY MOUTH

- Child (body-weight 30 kg and above): 1 tablet twice daily

- **UNLICENSED USE** *Trizivir*[®] not licensed for use in children.
- **INTERACTIONS** → Appendix 1: abacavir · lamivudine · zidovudine
- **RENAL IMPAIRMENT** Avoid *Trizivir*[®] if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Tablet

► *Trizivir* (ViiV Healthcare UK Ltd)

- Lamivudine 150 mg, Abacavir (as Abacavir sulfate) 300 mg, Zidovudine 300 mg *Trizivir* tablets | 60 tablet [PoM](#) £509.06

Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide

22-May-2019

The properties listed below are those particular to the combination only. For the properties of the components please consider, emtricitabine p. 453, elvitegravir, cobicistat, tenofovir alafenamide p. 434.

● INDICATIONS AND DOSE

HIV-1 infection (specialist use only)

► BY MOUTH

- Child 6–11 years (body-weight 25 kg and above): 1 tablet once daily
- Child 12–17 years (body-weight 35 kg and above): 1 tablet once daily

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: ELVITEGRAVIR BOOSTED WITH COBICISTAT: AVOID USE IN PREGNANCY DUE TO RISK OF TREATMENT FAILURE AND MATERNAL-TO-CHILD TRANSMISSION OF HIV-1 (APRIL 2019)

Pharmacokinetic data show mean exposure of elvitegravir boosted with cobicistat (available in combination in *Genvoya*[®] and *Stribild*[®]) to be lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. For further information, see *Pregnancy*.

- **INTERACTIONS** → Appendix 1: cobicistat · elvitegravir · tenofovir alafenamide
- **SIDE-EFFECTS**
 - **Common or very common** Abnormal dreams · diarrhoea · dizziness · fatigue · flatulence · gastrointestinal discomfort · headache · nausea · skin reactions · vomiting
 - **Uncommon** Anaemia · angioedema · depression
 - **Frequency not known** Nephrotoxicity · osteonecrosis · weight increased
- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception in women of childbearing potential; if using a hormonal contraceptive, it must contain drospirenone or norgestimate as the progestogen and at least 30 micrograms ethinylestradiol.
- **PREGNANCY** Manufacturer advises not to be initiated during pregnancy due to low elvitegravir exposure; women who become pregnant during therapy should be switched to an alternative regimen.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution (increased risk of hepatic side-effects); avoid in severe impairment (no information available).
- **RENAL IMPAIRMENT** Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—limited information available. Manufacturer advises caution in children under 12 years with renal impairment—no information available.